Philadelphia

Epidemiological Brief

As of 27 July 2026, Philadelphia is classified at LOW epidemic risk (composite score 9.5). Pertussis is the leading contributor at 1.52 cases per 100,000 (23.9% adjusted score). Influenza ILI stands at 2.6% (9.2% adjusted). COVID-19 activity is low at 0.19 cases per 100,000. Mpox is detected at 0.07 cases per 100,000, with the impact attenuated by the mitigation adjustment factor. Dengue is present only as travel importations at 0.03 cases per 100,000, with no local transmission. Measles data for Pennsylvania are not available in this surveillance cycle. Surveillance coverage is Low tier, limiting confidence in current incidence estimates. Wastewater-based epidemiology (ATCP-73RE) is actively monitoring COVID-19 signals. International arrivals number 3,416, presenting moderate importation exposure. Dry conditions prevail (24 °C, 55% humidity, no precipitation), limiting vector-borne disease risk. Recommended public health actions include pertussis surveillance and contact tracing, influenza rapid testing at medical posts, MMR vaccination verification for international spectators, routine mpox clinical screening pathways, dengue prevention advisories for travellers arriving from endemic regions, and timely disease reporting to the Philadelphia Department of Public Health and Pennsylvania DOH throughout the tournament.

Model SCEME v3.1 · Updated July 27, 2026

Please consult a local doctor or pharmacist for guidance and medication.